Kory James Wentworth
Chief Financial Officer · Entrada Therapeutics, Inc.
- 2024
- Sep 3, 2026
- 9
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Kory James Wentworth files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Kush Parmar - $3.65M in TRDA purchases and sales in the last 12 months
- MPM BIOVENTURES 2018, L.P. - $3.60M in TRDA purchases and sales in the last 12 months
- MPM BioVentures 2014, L.P. - $3.60M in TRDA purchases and sales in the last 12 months
- 5AM Ventures V, L.P. - $3.00M in TRDA purchases and sales in the last 12 months
- BAKER BROS. ADVISORS LP - $1.61M in TRDA purchases and sales in the last 12 months
- Nathan J. Dowden - $426K in TRDA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Kory James Wentworth?
Kory James Wentworth is a corporate insider, tracked as Chief Financial Officer of Entrada Therapeutics, Inc. (TRDA). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Kory James Wentworth submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Kory James Wentworth been buying or selling stock?
Recorded transactions: 0 open-market purchases and 8 open-market sales ($726K) across all tracked filings.
